+

WO2002102994A2 - Proteines secretees humaines - Google Patents

Proteines secretees humaines Download PDF

Info

Publication number
WO2002102994A2
WO2002102994A2 PCT/US2002/008278 US0208278W WO02102994A2 WO 2002102994 A2 WO2002102994 A2 WO 2002102994A2 US 0208278 W US0208278 W US 0208278W WO 02102994 A2 WO02102994 A2 WO 02102994A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
polypeptide
referenced
fragment
encoded
Prior art date
Application number
PCT/US2002/008278
Other languages
English (en)
Other versions
WO2002102994A3 (fr
Inventor
Craig A. Rosen
Steven M. Ruben
Original Assignee
Human Genome Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences, Inc. filed Critical Human Genome Sciences, Inc.
Priority to CA002441832A priority Critical patent/CA2441832A1/fr
Priority to EP02760994A priority patent/EP1379132A4/fr
Priority to AU2002326293A priority patent/AU2002326293A1/en
Publication of WO2002102994A2 publication Critical patent/WO2002102994A2/fr
Publication of WO2002102994A3 publication Critical patent/WO2002102994A3/fr
Priority to US11/346,470 priority patent/US20060223088A1/en
Priority to US12/198,817 priority patent/US7968689B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to human secreted proteins/polypeptides, and isolated nucleic acid molecules encoding said proteins/polypeptides, useful for detecting, preventing, diagnosing, prognosticating, treating, and/or ameliorating immune disorders and diseases.
  • Antibodies that bind these polypeptides are also encompassed by the present invention.
  • vectors, host cells, and recombinant and synthetic methods for producing said polynucleotides, polypeptides, and/or antibodies are also encompassed by the present invention.
  • the invention further encompasses screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention.
  • the present invention further encompasses methods and compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.
  • the immune system is an intricate network of cells, tissues and soluble molecules that function to protect the body from invasion by foreign substances and pathogens.
  • the major cells of the immune system are lymphocytes, including B cells and T cells, and myeloid cells, including basophils, eosinophils, neutrophils, mast cells, monocytes, macrophages and dendritic cells.
  • lymphocytes including B cells and T cells
  • myeloid cells including basophils, eosinophils, neutrophils, mast cells, monocytes, macrophages and dendritic cells.
  • soluble molecules- such as antibodies, complement proteins, and cytokines- circulate in lymph and blood plasma, and play important roles in immunity.
  • the immune system can be subdivided into the acquired and innate immune systems.
  • the cells of the innate immune system e.g., neutrophils, eosinophils, basophils, mast cells
  • the cells of the acquired immune system B and T cells
  • B and T cells are antigen specific. Repeated exposure of B and T cells to an antigen results in improved immune responses (memory responses) produced by these cell types.
  • the cells and products of the acquired immune system can recruit components of the innate system to mount a focused immune response.
  • An immune response is seldom carried out by a single cell type, but rather requires the coordinated efforts of several cell types.
  • cells of the immune system communicate with each other and with other cells of the body. Communication between cells may be made by cell-cell contact, between membrane bound molecules on each cell, or by the interaction of soluble components of the immune system with cellular receptors. Signaling between cell types may have one or more of a variety of consequences, including activation, proliferation, differentiation, and apoptosis. Activation and differentiation of immune cells may result in the expression or secretion of polypeptides, or other molecules, which in turn affect the function of other cells and/or molecules of the immune system. Molecules which stimulate or suppress immune system function are known as immunomodulators.
  • Immunomodulators may enhance (immunoprophylaxis, immunostimulation), restore (immunosubstitution, immunorestoration) or suppress (immunosuppression, immunodeviation) immunological functions or activities.
  • Immunomodulatory compounds have many important applications in clinical practice.
  • immunosuppressing agents which attenuate or prevent unwanted immune responses
  • a mechanism of action common to many immunosuppressants is the inhibition of T cell activation and/or differentiation.
  • Antilymphocyte antibodies have also been used to attenuate immune system functions.
  • Currently- used immunosuppressive agents can produce a number of side effects which limit their use. Among the most serious secondary effects include kidney and liver toxicity, increased risk of infection, hyperglycemia, neoplasia, and osteoporosis (see, e.g., Freeman, Clin. Biochem. 24(1):9- 14 (1991); Mitchison, Dig. Dis.ll(2):78-101 (1993)).
  • Immunostimulants which enhance the activity of immune cells and molecules, comprise another class of immunomodulatory agents with important clinical applications. Such applications include, for example, the treatment of immunodeficiency disorders (e.g. AIDS and severe combined immunodeficiency), chronic infectious diseases (e.g. viral hepatitis, papillomavirus, and herpesvirus), and cancer.
  • immunodeficiency disorders e.g. AIDS and severe combined immunodeficiency
  • chronic infectious diseases e.g. viral hepatitis, papillomavirus, and herpesvirus
  • cancer An important class of endogenous immunostimulants is the cytokines. These soluble signaling molecules are produced by a number of cell types, and are critical to the regulation of the immune response. Immunostimulatory mechanisms can include proliferation, differentiation and/or activation of immune cells or progenitors of immune cells.
  • interleukin-2 binds to IL-2 receptors on T lymphocytes and induces proliferation and differentiation.
  • Another cytokine, interferon alpha stimulates the immune system through a variety of mechanisms, including activation of macrophages, T lymphocytes, and natural killer cells. Interferon alpha also induces the expression of antiviral proteins (see Chapter 50, The Pharmacological Basis of Therapeutics. 9 th Edition, Eds. Hardman, Limbird, Molinoff, Ruddon, and Gilman, McGraw Hill (1996)). Limitations of current immunostimulant therapies include anaphylaxis, pulmonary edema, and renal toxicity, to name a few.
  • autoimmune disorders e.g., systemic lupus erythematosus, rheumatoid arthritis, idiopathic thrombocytopenic purpura and multiple sclerosis
  • immunodeficiencies e.g., X-linked agammaglobulinemia, severe combined immunodeficiency, Wiskott-Aldrich syndrome, and ataxia telangiectasia
  • chronic infections e.g., HIV, viral hepatitis, and herpesvirus
  • neoplastic disorders See, e.g. "Immune Activity" section infra.
  • immune related molecules would be useful as agents to
  • the present invention encompasses human secreted proteins/polypeptides, and isolated nucleic acid molecules encoding said proteins/polypeptides, useful for detecting, preventing, diagnosing, prognosticating, treating, and/or ameliorating immune disorders and diseases.
  • Antibodies that bind these polypeptides are also encompassed by the present invention; as are vectors, host cells, and recombinant and synthetic methods for producing said polynucleotides, polypeptides, and/or antibodies.
  • the invention further encompasses screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention.
  • the present invention also encompasses methods and compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.
  • Table 1A summarizes information concerning certain polypnucleotides and polypeptides of the invention.
  • the first column provides the gene number in the application for each clone identifier.
  • the second column provides a unique clone identifier, "Clone ID:”, for a cDNA clone related to each contig sequence disclosed in Table 1A.
  • Third column the cDNA
  • Clones identified in the second column were deposited as indicated in the third column (i.e. by ATCC Deposit No:Z and deposit date). Some of the deposits contain multiple different clones corresponding to the same gene.
  • Vector refers to the type of vector contained in the corresponding cDNA Clone identified in the second column.
  • the nucleotide sequence identified as "NT SEQ ID NO:X” was assembled from partially homologous ("overlapping") sequences obtained from the corresponding cDNA clone identified in the second column and, in some cases, from additional related cDNA clones.
  • Total NT Seq refers to the total number of nucleotides in the contig sequence identified as SEQ ID NO:X.”
  • the deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as "5' NT of Clone Seq.” (seventh column) and the "3' NT of Clone Seq.” (eighth column) of SEQ ID NO:X.
  • nucleotide position of SEQ ID NO:X of the putative start codon is identified as "5' NT of Start Codon.”
  • nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as "5' NT of First AA of Signal Pep.”
  • the translated amino acid sequence, beginning with the methionine is identified as "AA SEQ ID NO:Y,” although other reading frames can also be routinely translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.
  • the first and last amino acid position of SEQ ID NO: Y of the predicted signal peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep.”
  • the predicted first amino acid position of SEQ ID NO: Y of the secreted portion is identified as "Predicted First AA of Secreted Portion”.
  • the amino acid position of SEQ ID NO:Y of the last amino acid encoded by the open reading frame is identified in the fifteenth column as "Last AA of ORF”.
  • SEQ ID NO:X (where X may be any of the polynucleotide sequences disclosed in the sequence listing) and the translated SEQ ID NO:Y (where Y may be any of the polypeptide sequences disclosed in the sequence listing) are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below.
  • SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in the deposited clone. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention.
  • polypeptides identified from SEQ ID NO:Y may be used, for example, to generate antibodies which bind specifically to proteins containing the polypeptides and the secreted proteins encoded by the cDNA clones identified in Table 1A and/or elsewhere herein Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors.
  • the errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence.
  • the erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).
  • the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X, and the predicted translated amino acid sequence identified as SEQ ID NO: Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table 1A.
  • the nucleotide sequence of each deposited plasmid can readily be determined by sequencing the deposited plasmid in accordance with known methods The predicted amino acid sequence can then be verified from such deposits.
  • amino acid sequence of the protein encoded by a particular plasmid can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.
  • Table 1A Also provided in Table 1A is the name of the vector which contains the cDNA plasmid. Each vector is routinely used in the art. The following additional information is provided for convenience.
  • pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene.
  • Phagemid pBS may be excised from the Lambda Zap and Uni-Zap XR vectors, and phagemid pBK may be excised from the Zap Express vector. Both phagemids may be transformed into E. coli strain XL-1 Blue, also available from Stratagene
  • Vectors pSportl, pCMVSport 1.0, pCMVSport 2.0 and pCMVSport 3.0 were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. See, for instance, Gruber, C. E., et al., Focus 75:59 (1993). Vector lafmid BA (Bento Soares, Columbia University, New York, NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue.
  • Vector pCR ® 2.1 which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. See, for instance, Clark, J. M., Nuc. Acids Res. 76:9677-9686 (1988) and Mead, D. et al, Bio/Technology 9: (1991).
  • the present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:X, SEQ ID NO:
  • allelic variants, orthologs, and/or species homologs Procedures known in the art can be used to obtain full-length genes, allelic variants, splice variants, full-length coding portions, orthologs, and/or species homologs of genes corresponding to SEQ ID NO:X and SEQ ID NO:Y using information from the sequences disclosed herein or the clones deposited with the ATCC.
  • allelic variants and/or species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for allelic variants and/or the desired homologue.
  • the present invention provides a polynucleotide comprising, or alternatively consisting of, the nucleic acid sequence of SEQ ID NO:X and/or a cDNA contained in ATCC Deposit No.Z.
  • the present invention also provides a polypeptide comprising, or alternatively, consisting of, the polypeptide sequence of SEQ ID NO:Y, a polypeptide encoded by SEQ ID NO:X, and/or a polypeptide encoded by a cDNA contained in ATCC deposit No.Z.
  • Polynucleotides encoding a polypeptide comprising, or alternatively consisting of the polypeptide sequence of SEQ ID NO:Y, a polypeptide encoded by SEQ ID NO:X and/or a polypeptide encoded by the cDNA contained in ATCC Deposit No.Z, are also encompassed by the invention.
  • the present invention further encompasses a polynucleotide comprising, or alternatively consisting of the complement of the nucleic acid sequence of SEQ ID NO:X, and/or the complement of the coding strand of the cDNA contained in ATCC Deposit No.Z.
  • Table IB.l and Table 1B.2 summarize some of the polynucleotides encompassed by the invention (including cDNA clones related to the sequences (Clone ID:), contig sequences (contig identifier (Contig ID:) and contig nucleotide sequence identifiers (SEQ ID NO:X)) and further summarizes certain characteristics of these polynucleotides and the polypeptides encoded thereby.
  • the first column of Tables IB.l and 1B.2 provide the gene numbers in the application for each clone identifier.
  • the second column of Tables IB.l and 1B.2 provide unique clone identifiers, "Clone ID:”, for cDNA clones related to each contig sequence disclosed in Table 1A and/or Table IB.
  • the third column of Tables IB.l and 1B.2 provide unique contig identifiers, "Contig ID:” for each of the contig sequences disclosed in these tables.
  • the fourth column of Tables IB.l and 1B.2 provide the sequence identifiers, "SEQ ID NO:X", for each of the contig sequences disclosed in Table 1A and or IB.
  • the fifth column of Table IB.l provides the location (i.e., nucleotide position numbers) within the polynucleotide sequence of SEQ ID NO:X that delineates the preferred open reading frame (ORF) that encodes the amino acid sequence shown in the sequence listing and referenced in Table IB.l as SEQ ID NO:Y (column 6).
  • Column 7 of Table IB.l lists residues comprising predicted epitopes contained in the polypeptides encoded by each of the preferred ORFs (SEQ ID NO:Y).
  • polypeptides of the invention comprise, or alternatively consist of, one, two, three, four, five or more of the predicted epitopes described in Table IB.l. It will be appreciated that depending on the analytical criteria used to predict antigenic determinants, the exact address of the determinant may vary slightly.
  • Column 8 of Table IB.l (“Cytologic Band") provides the chromosomal location of polynucleotides corresponding to SEQ ED NO:X. Chromosomal location was determined by finding exact matches to EST and cDNA sequences contained in the NCBI (National Center for Biotechnology Information) UniGene database.
  • Table IB.l Column 9 labeled "OMIM Disease Reference(s)".
  • OMIM Disease Reference(s) A key to the OMEM reference identification numbers is provided in Table 5.
  • Table 1B.2 Column 5 of Table 1B.2, 'Tissue Distribution" shows the expression profile of tissue, cells, and/or cell line libraries which express the polynucleotides of the invention. The first code number shown in Table 1B.2 column 5 (preceding the colon), represents the tissue/cell source identifier code corresponding to the key provided in Table 4. Expression of these polynucleotides was not observed in the other tissues and/or cell libraries tested.
  • the second number in column 5 represents the number of times a sequence corresponding to the reference polynucleotide sequence (e.g., SEQ ID NO:X) was identified in the corresponding tissue/cell source.
  • tissue/cell source identifier codes in which the first two letters are "AR" designate information generated using DNA array technology.
  • cDNAs were amplified by PCR and then transferred, in duplicate, onto the array. Gene expression was assayed through hybridization of first strand cDNA probes to the DNA array.
  • cDNA probes were generated from total RNA extracted from a variety of different tissues and cell lines. Probe synthesis was performed in the presence of 33 P dCTP, using oligo(dT) to prime reverse transcription.
  • Table 1C summarizes additional polynucleotides encompassed by the invention (including cDNA clones related to the sequences (Clone ED:), contig sequences (contig identifier (Contig ED:) contig nucleotide sequence identifiers (SEQ ED NO:X)), and genomic sequences (SEQ ED NO:B).
  • the first column provides a unique clone identifier, "Clone TD:”, for a cDNA clone related to each contig sequence.
  • the second column provides the sequence identifier, "SEQ ID NO:X”, for each contig sequence.
  • the third column provides a unique contig identifier, "Contig ED:” for each contig sequence.
  • the fourth column provides a BAC identifier "BAC ED NO:A” for the BAC clone referenced in the corresponding row of the table.
  • the fifth column provides the nucleotide sequence identifier, "SEQ ED NO:B" for a fragment of the BAC clone identified in column four of the corresponding row of the table.
  • the sixth column "Exon From- To" provides the location (i.e., nucleotide position numbers) within the polynucleotide sequence of SEQ ID NO:B which delineate certain polynucleotides of the invention that are also exemplary members of polynucleotide sequences that encode polypeptides of the invention (e.g., polypeptides containing amino acid sequences encoded by the polynucleotide sequences delineated in column six, and fragments and variants thereof).
  • the present invention encompasses a method of detecting, preventing, diagnosing, prognosticating, treating, and/or ameliorating immune diseases or disorders; comprising administering to a patient in which such treatment, prevention, or amelioration is desired a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) represented by Table 1A, Table IB, and Table 1C, in an amount effective to detect, prevent, diagnose, prognosticate, treat, and/or ameliorate the disease or disorder.
  • the polynucleotides, polypeptides, agonists, or antagonists of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides or polypeptides, or agonists or antagonists thereof (including antibodies) could be used to treat the associated disease.
  • Table ID provides information related to biological activities for polynucleotides and polypeptides of the invention (including antibodies, agonists, and/or antagonists thereof). Table ID also provides information related to assays which may be used to test polynucleotides and polypeptides of the invention (including antibodies, agonists, and/or antagonists thereof) for the corresponding biological activities.
  • the first column (“Gene No.") provides the gene number in the application for each clone identifier.
  • the second column (“cDNA Clone ED:”) provides the unique clone identifier for each clone as previously described and indicated in Tables 1A, IB, and lC.
  • the third column (“AA SEQ ID NO:Y”) indicates the Sequence Listing SEQ ED Number for polypeptide sequences encoded by the corresponding cDNA clones (also as indicated in Tables 1A, IB, and 2).
  • the fourth column (“Biological Activity”) indicates a biological activity corresponding to the indicated polypeptides (or polynucleotides encoding said polypeptides).
  • the fifth column (“Exemplary Activity Assay”) further describes the corresponding biological activity and provides information pertaining to the various types of assays which may be performed to test, demonstrate, or quantify the corresponding biological activity. Table ID describes the use of FMAT technology, inter alia, for testing or demonstrating various biological activities.
  • Fluorometric microvolume assay technology is a fluorescence-based system that provides a means to perform nonradioactive cell- and bead-based assays to detect activation of cell signal transduction pathways. This technology was designed specifically for ligand binding and immunological assays. Using this technology, fluorescent cells or beads at the bottom of the well are detected as localized areas of concentrated fluorescence using a data processing system. Unbound flurophore comprising the background signal is ignored, allowing for a wide variety of homogeneous assays. FMAT technology may be used for peptide ligand binding assays, immunofluorescence, apoptosis, cytotoxicity, and bead-based immunocapture assays.
  • FMAT technology may be used to test, confirm, and/or identify the ability of polypeptides (including polypeptide fragments and variants) to activate signal transduction pathways.
  • FMAT technology may be used to test, confirm, and/or identify the ability of polypeptides to upregulate production of immunomodulatory proteins (such as, for example, interleukins, GM-CSF, Rantes, and Tumor Necrosis factors, as well as other cellular regulators (e.g. insulin)).
  • immunomodulatory proteins such as, for example, interleukins, GM-CSF, Rantes, and Tumor Necrosis factors, as well as other cellular regulators (e.g. insulin)
  • Table ID also describes the use of kinase assays for testing, demonstrating, or quantifying biological activity.
  • the phosphorylation and de-phosphorylation of specific amino acid residues e.g. Tyrosine, Serine, Threonine
  • cell-signal transduction proteins provides a fast, reversible means for activation and de-activation of cellular signal transduction pathways.
  • cell signal transduction via phosphorylation/de-phosphorylation is crucial to the regulation of a wide variety of cellular processes (e.g. proliferation, differentiation, migration, apoptosis, etc.).
  • kinase assays provide a powerful tool useful for testing, confirming, and/or identifying polypeptides (including polypeptide fragments and variants) that mediate cell signal transduction events via protein phosphorylation. See e.g., Forrer, P., Tamaskovic R., and Jaussi, R. "Enzyme-Linked Immunosorbent Assay for Measurement of JNK, ERK, and p38 Kinase Activities" Biol. Chem. 379(8-9): 1101-1110 (1998).
  • Polynucleotides encoding polypeptides of the present invention can be used in assays to test for one or more biological activities.
  • One such biological activity which may be tested includes the ability of polynucleotides and polypeptides of the invention to stimulate up-regulation or down-regulation of expression of particular genes and proteins.
  • polynucleotides and polypeptides of the present invention exhibit activity in altering particular gene and protein expression patterns, it is likely that these polynucleotides and polypeptides of the present invention may be involved in, or capable of effecting changes in, diseases associated with the altered gene and protein expression profiles.
  • polynucleotides, polypeptides, or antibodies of the present invention could be used to treat said associated diseases.
  • TaqMan® assays may be performed to assess the ability of polynucleotides (and polypeptides they encode) to alter the expression pattern of particular "target" genes.
  • TaqMan® reactions are performed to evaluate the ability of a test agent to induce or repress expression of specific genes in different cell types.
  • TaqMan® gene expression quantification assays ('TaqMan® assays") are well known to, and routinely performed by, those of ordinary skill in the art.
  • TaqMan® assays are performed in a two step reverse transcription / polymerase chain reaction (RT-PCR). Ln the first (RT) step, cDNA is reverse transcribed from total RNA samples using random hexamer primers. In the second (PCR) step, PCR products are synthesized from the cDNA using gene specific primers.
  • RT-PCR reverse transcription / polymerase chain reaction
  • the Taqman® PCR reaction exploits the 5' nuclease activity of AmpliTaq Gold ® DNA Polymerase to cleave a Taqman® probe (distinct from the primers) during PCR.
  • the Taqman® probe contains a reporter dye at the 5 '-end of the probe and a quencher dye at the 3' end of the probe. When the probe is intact, the proximity of the reporter dye to the quencher dye results in suppression of the reporter fluorescence.
  • the probe specifically anneals between the forward and reverse primer sites.
  • AmpliTaq Fold DNA Polymerase then cleaves the probe between the reporter and quencher when the probe hybridizes to the target, resulting in increased fluorescence of the reporter (see Figure 2). Accumulation of PCR products is detected directly by monitoring the increase in fluorescence, of the reporter dye.
  • vector controls or constructs containing the coding sequence for the gene of interest are transfected into cells, such as for example 293T cells, and supernatants collected after 48 hours.
  • cells such as for example 293T cells
  • multiple primary human cells or human cell lines are used; such cells may include but are not limited to, Normal Human Dermal Fibroblasts, Aortic Smooth Muscle, Human Umbilical Vein Endothelial Cells, HepG2, Daudi, Jurkat, U937, Caco, and THP-1 cell lines.
  • Cells are plated in growth media and growth is arrested by culturing without media change for 3 days, or by switching cells to low serum media and incubating overnight.
  • RNA is isolated; for example, by using Trizol extraction or by using the Ambion RNAqueous(TM)-4PCR RNA isolation system. Expression levels of multiple genes are analyzed using TAQMAN, and expression in the test sample is compared to control vector samples to identify genes induced or repressed.
  • Table IE indicates particular disease classes and preferred indications for which polynucleotides, polypeptides, or antibodies of the present invention may be used in detecting, diagnosing, preventing, treating and/or ameliorating said diseases and disorders based on "target" gene expression patterns which may be up- or down-regulated by polynucleotides (and the encoded polypeptides) corresponding to each indicated cDNA Clone ID (shown in Table IE, Column 2).
  • the present invention encompasses a method of detecting, diagnosing, preventing, treating, and/or ameliorating a disease or disorder listed in the "Disease Class" and/or "Preferred Indication” columns of Table IE; comprising administering to a patient in which such detection, diagnosis, prevention, or treatment is desired a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) in an amount effective to detect, diagnose, prevent, treat, or ameliorate the disease or disorder.
  • the first and second columns of Table ID show the "Gene No.” and "cDNA Clone ED No.”, respectively, indicating certain nucleic acids and proteins (or antibodies against the same) of the invention (including polynucleotide, polypeptide, and antibody fragments or variants thereof) that may be used in detecting, diagnosing, preventing, treating, or ameliorating the disease(s) or disorder(s) indicated in the corresponding row in the "Disease Class” or "Preferred Indication” Columns of Table IE.
  • the present invention also encompasses methods of detecting, diagnosing, preventing, treating, or ameliorating a disease or disorder listed in the "Disease Class” or "Preferred Indication” Columns of Table IE; comprising administering to a patient combinations of the proteins, nucleic acids, or antibodies of the invention (or fragments or variants thereof), sharing similar indications as shown in the corresponding rows in the "Disease Class” or “Preferred Indication” Columns of Table IE.
  • the "Disease Class” Column of Table IE provides a categorized descriptive heading for diseases, disorders, and/or conditions (more fully described below) that may be detected, diagnosed, prevented, treated, or ameliorated by a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof).
  • the "Preferred Indication” Column of Table IE describes diseases, disorders, and/or conditions that may be detected, diagnosed, prevented, treated, or ameliorated by a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof).
  • Cell Line and “Exemplary Targets” Columns of Table IE indicate particular cell lines and target genes, respectively, which may show altered gene expression patterns (i.e., up- or down-regulation of the indicated target gene) in Taqman assays, performed as described above, utilizing polynucleotides of the cDNA Clone ED shown in the corresponding row. Alteration of expression patterns of the indicated “Exemplary Target” genes is correlated with a particular "Disease Class” and/or "Preferred Indication” as shown in the corresponding row under the respective column headings.
  • Cancer in the "Disease Class” Column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof) may be used for example, to detect, diagnose, prevent, treat, and/or ameliorate neoplastic diseases and/or disorders (e.g., leukemias, cancers, etc., as described below under “Hyperproliferative Disorders”).
  • neoplastic diseases and/or disorders e.g., leukemias, cancers, etc., as described below under “Hyperproliferative Disorders”
  • “Hyperproliferative Disorders” blood disorders (e.g., as described below under “Immune Activity” “Cardiovascular Disorders” and/or “Blood-Related Disorders”), and infections (e.g., as described below under “Infectious Disease”).
  • Angiogenesis in the "Disease Class” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to detect, diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under "Hyperproliferative Disorders"), diseases and/or disorders of the cardiovascular system (e.g., as described below under "Cardiovascular Disorders"), diseases and/or disorders involving cellular and genetic abnormalities (e.g., as described below under "Diseases at the Cellular Level"), diseases and or disorders involving angiogenesis (e.g., as described below under "Anti- Angiogenesis Activity”), to promote or inhibit cell or tissue regeneration (e.g., as described below under "Regeneration”), or to promote wound healing (e.g., as described below under "Wound Healing and Epithelial Cell Proliferation”).
  • neoplastic diseases e
  • Diabetes in the "Disease Class” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to detect, diagnose, treat, prevent, and/or ameliorate diabetes (including diabetes mellitus types I and IE), as well as diseases and/or disorders associated with, or consequential to, diabetes (e.g. as described below under “Endocrine Disorders,” “Renal Disorders,” and “Gastrointestinal Disorders”). Description of Table 2
  • Table 2 summarizes homology and features of some of the polypeptides of the invention.
  • the first column provides a unique clone identifier, "Clone D:”, corresponding to a cDNA clone disclosed in Table 1A or Table IB.
  • the second column provides the unique contig identifier, "Contig ED:” corresponding to contigs in Table IB and allowing for correlation with the information in Table IB.
  • the third column provides the sequence identifier, "SEQ D NO:X", for the contig polynucleotide sequence.
  • the fourth column provides the analysis method by which the homology/identity disclosed in the Table was determined.
  • NR non-redundant protein database
  • PFAM protein families
  • polypeptides of the invention comprise, or alternatively consist of, an amino acid sequence encoded by a polynucleotide in SEQ ED NO:X as delineated in columns 8 and 9, or fragments or variants thereof.
  • Table 3 provides polynucleotide sequences that may be disclaimed according to certain embodiments of the invention.
  • the first column provides a unique clone identifier, "Clone ID”, for a cDNA clone related to contig sequences disclosed in Table IB.
  • the second column provides the sequence identifier, "SEQ ED NO:X”, for contig sequences disclosed in Table 1A and/or Table IB.
  • the third column provides the unique contig identifier, "Contig ED:”, for contigs disclosed in Table IB.
  • the fourth column provides a unique integer 'a' where 'a' is any integer between 1 and the final nucleotide minus 15 of SEQ ED NO:X
  • the fifth column provides a unique integer 'b' where 'b' is any integer between 15 and the final nucleotide of SEQ ED NO:X, where both a and b correspond to the positions of nucleotide residues shown in SEQ TD NO:X, and where b is greater than or equal to a + 14.
  • the uniquely defined integers can be substituted into the general formula of a-b, and used to describe polynucleotides which may be preferably excluded from the invention.
  • preferably excluded from the invention are at least one, two, three, four, five, ten, or more of the polynucleotide sequence(s) having the accession number(s) disclosed in the sixth column of this Table (including for example, published sequence in connection with a particular BAC clone).
  • preferably excluded from the invention are the specific polynucleotide sequence(s) contained in the clones corresponding to at least one, two, three, four, five, ten, or more of the available material having the accession numbers identified in the sixth column of this Table (including for example, the actual sequence contained in an identified BAC clone).
  • Table 4 provides a key to the tissue/cell source identifier code disclosed in Table IB.2, column 5.
  • Column 1 provides the tissue/cell source identifier code disclosed in Table 1B.2, Column 5.
  • Columns 2-5 provide a description of the tissue or cell source. Note that "Description” and “Tissue” sources (i.e. columns 2 and 3) having the prefix “a_” indicates organs, tissues, or cells derived from “adult” sources. Codes corresponding to diseased tissues are indicated in column 6 with the word “disease.” The use of the word “disease” in column 6 is non-limiting.
  • the tissue or cell source may be specific (e.g.
  • tissue/cell source is a library
  • column 7 identifies the vector used to generate the library.
  • Table 5 provides a key to the OMEM reference identification numbers disclosed in Table IB.l, column 9.
  • OMEM reference identification numbers (Column 1) were derived from Online Mendelian Inheritance in Man (Online Mendelian Inheritance in Man, OMIM. McKusick- Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine, (Bethesda, MD) 2000. World Wide Web URL: http://www.ncbi.nlm.nih.gov/omim/).
  • Column 2 provides diseases associated with the cytologic band disclosed in Table IB.l, column 8, as determined using the Morbid Map database.
  • Table 6 summarizes some of the ATCC Deposits, Deposit dates, and ATCC designation numbers of deposits made with the ATCC in connection with the present application. These deposits were made in addition to those described in the Table 1A.
  • Table 7 shows the cDNA libraries sequenced, and ATCC designation numbers and vector information relating to these cDNA libraries.
  • the first column shows the first four letters indicating the Library from which each library clone was derived.
  • the second column indicates the catalogued tissue description for the corresponding libraries.
  • the third column indicates the vector containing the corresponding clones.
  • the fourth column shows the ATCC deposit designation for each libray clone as indicated by the deposit information in Table 6.
  • isolated refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered “by the hand of man” from its natural state.
  • an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be “isolated” because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide.
  • isolated does not refer to genomic or cDNA libraries, whole cell total or mRNA preparations, genomic DNA preparations (including those separated by electrophoresis and transferred onto blots), sheared whole cell genomic DNA preparations or other compositions where the art demonstrates no distinguishing features of the polynucleotide/sequences of the present invention.
  • a "secreted” protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.
  • a "polynucleotide” refers to a molecule having a nucleic acid sequence encoding SEQ ED NO:Y or a fragment or variant thereof (e.g., the polypeptide delinated in columns fourteen and fifteen of Table 1A); a nucleic acid sequence contained in SEQ TD NO:X (as described in column 5 of Table 1A and/or Table IB) or the complement thereof; a cDNA sequence contained in Clone ED: (as described in column 2 of Table 1A and/or Table IB and contained within a library deposited with the ATCC); a nucleotide sequence encoding the polypeptide encoded by a nucleotide sequence in SEQ ED NO:B as defined in column 6 (EXON From-To) of Table 1C or a fragment or variant thereof; or a nucleotide coding sequence in SEQ ED NO:B as defined in column 6 of Table 1C or the complement thereof.
  • the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence.
  • a "polypeptide” refers to a molecule having an amino acid sequence encoded by a polynucleotide of the invention as broadly defined (obviously excluding poly-Phenylalanine or poly-Lysine peptide sequences which result from translation of a polyA tail of a sequence corresponding to a cDNA).
  • SEQ ED NO:X was often generated by overlapping sequences contained in multiple clones (contig analysis).
  • a representative clone containing all or most of the sequence for SEQ TD NO:X is deposited at Human Genome Sciences, Inc. (HGS) in a catalogued and archived library.
  • HGS Human Genome Sciences, Inc.
  • each clone is identified by a cDNA Clone ED (identifier generally referred to herein as Clone ED:).
  • Clone ED identifier generally referred to herein as Clone ED:
  • Each Clone ID is unique to an individual clone and the Clone ED is all the information needed to retrieve a given clone from the HGS library.
  • Table 7 provides a list of the deposited cDNA libraries.
  • Table 7 lists the deposited cDNA libraries by name and links each library to an ATCC Deposit. Library names contain four characters, for example, "HTWE.” The name of a cDNA clone (Clone ED) isolated from that library begins with the same four characters, for example "HTWEP07".
  • Table 1A and/or Table IB correlates the Clone ED names with SEQ ID NO:X. Thus, starting with an SEQ ED NO:X, one can use Tables 1A, IB, 6, 7, and 9 to determine the corresponding Clone ED, which library it came from and which ATCC deposit the library is contained in.
  • the ATCC is located at 10801 University Boulevard, Manassas, Virginia 20110-2209, USA.
  • the ATCC deposits were made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for the purposes of patent procedure.
  • the polynucleotides of the invention are at least 15, at least 30, at least 50, at least 100, at least 125, at least 500, or at least 1000 continuous nucleotides but are less than or equal to 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, 7.5kb, 5 kb, 2.5 kb, 2.0 kb, or 1 kb, in length.
  • polynucleotides of the invention comprise a portion of the coding sequences, as disclosed herein, but do not comprise all or a portion of any intron.
  • the polynucleotides comprising coding sequences do not contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the gene of interest in the genome). In other embodiments, the polynucleotides of the invention do not contain the coding sequence of more than 1000, 500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or 1 genomic flanking gene(s).
  • a "polynucleotide” of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ED NO:X, or the complement thereof (e.g., the complement of any one, two, three, four, or more of the polynucleotide fragments described herein), the polynucleotide sequence delineated in columns 7 and 8 of Table 1A or the complement thereof, the polynucleotide sequence delineated in columns 8 and 9 of Table 2 or the complement thereof, and/or cDNA sequences contained in Clone ED: (e.g., the complement of any one, two, three, four, or more of the polynucleotide fragments, or the cDNA clone within the pool of cDNA clones deposited with the ATCC, described herein), and or the polynucleotide sequence delineated in column 6 of Table 1C or the complement thereof.
  • SEQ ED NO:X or the
  • “Stringent hybridization conditions” refers to an overnight incubation at 42 degree C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 ⁇ g/ml denatured, sheared salmon sperm DNA, followed by washing the filters in O.lx SSC at about 65 degree C. Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions.
  • Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature.
  • washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).
  • blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations.
  • the inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.
  • polynucleotide which hybridizes only to polyA ⁇ sequences (such as any 3' terminal polyA ⁇ tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide,” since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone generated using oligo dT as a primer).
  • polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA.
  • polynucleotides can be composed of single- and double- stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double- stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions.
  • polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA.
  • a polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons.
  • Modified bases include, for example, tritylated bases and unusual bases such as inosine.
  • a variety of modifications can be made to DNA and RNA; thus, "polynucleotide” embraces chemically, enzymatically, or metabolically modified forms.
  • the polynucleotides of the invention are at least 15, at least 30, at least 50, at least 100, at least 125, at least 500, or at least 1000 continuous nucleotides but are less than or equal to 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, 7.5kb, 5 kb, 2.5 kb, 2.0 kb, or 1 kb, in length.
  • polynucleotides of the invention comprise a portion of the coding sequences, as disclosed herein, but do not comprise all or a portion of any intron.
  • the polynucleotides comprising coding sequences do not contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the gene of interest in the genome). In other embodiments, the polynucleotides of the invention do not contain the coding sequence of more than 1000, 500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or 1 genomic flanking gene(s).
  • SEQ ID NO:X refers to a polynucleotide sequence described in column 5 of Table 1A
  • SEQ ID NO:Y refers to a polypeptide sequence described in column 10 of Table 1A
  • SEQ ED NO:X is identified by an integer specified in column 6 of Table 1A.
  • the polypeptide sequence SEQ ED NO:Y is a translated open reading frame (ORF) encoded by polynucleotide SEQ ED NO:X.
  • the polynucleotide sequences are shown in the sequence listing immediately followed by all of the polypeptide sequences.
  • a polypeptide sequence corresponding to polynucleotide sequence SEQ ED NO: 2 is the first polypeptide sequence shown in the sequence listing.
  • the second polypeptide sequence corresponds to the polynucleotide sequence shown as SEQ ED NO:3, and so on.
  • the polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids.
  • the polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini.
  • polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods.
  • Modifications include acetylation, acylation, ADP- ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.
  • SEQ ED NO:X refers to a polynucleotide sequence described, for example, in Tables 1A, Table IB, or Table 2, while “SEQ ED NO:Y” refers to a polypeptide sequence described in column 11 of Table 1A and or Table IB. SEQ ED NO:X is identified by an integer specified in column 4 of Table IB. The polypeptide sequence SEQ ID NO:Y is a translated open reading frame (ORF) encoded by polynucleotide SEQ TD NO:X. "Clone ED:” refers to a cDNA clone described in column 2 of Table 1A and/or IB.
  • a polypeptide having functional activity refers to a polypeptide capable of displaying one or more known functional activities associated with a full-length (complete) protein. Such functional activities include, but are not limited to, biological activity (e.g. activity useful in treating, preventing and/or ameliorating immune diseases and disorders), antigenicity (ability to bind [or compete with a polypeptide for binding] to an anti-polypeptide antibody), immunogenicity (ability to generate antibody which binds to a specific polypeptide of the invention), ability to form multimers with polypeptides of the invention, and ability to bind to a receptor or ligand for a polypeptide.
  • the polypeptides of the invention can be assayed for functional activity (e.g.
  • a polypeptide having biological activity refers to a polypeptide exhibiting activity similar to, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention).
  • Table 1A summarizes information concerning certain polypnucleotides and polypeptides of the invention.
  • the first column provides the gene number in the application for each clone identifier.
  • the second column provides a unique clone identifier, "Clone ED:”, for a cDNA clone related to each contig sequence disclosed in Table 1A.
  • Third column the cDNA Clones identified in the second column were deposited as indicated in the third column (i.e. by ATCC Deposit No:Z and deposit date). Some of the deposits contain multiple different clones corresponding to the same gene.
  • “Vector” refers to the type of vector contained in the corresponding cDNA Clone identified in the second column.
  • nucleotide sequence identified as "NT SEQ TD NO:X” was assembled from partially homologous ("overlapping") sequences obtained from the corresponding cDNA clone identified in the second column and, in some cases, from additional related cDNA clones.
  • the overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ TD NO:X.
  • Total NT Seq refers to the total number of nucleotides in the contig sequence identified as SEQ ED NO:X.”
  • the deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as "5' NT of Clone Seq.” (seventh column) and the "3' NT of Clone Seq.” (eighth column) of SEQ TD NO:X.
  • the nucleotide position of SEQ ED NO:X of the putative start codon (methionine) is identified as "5' NT of Start Codon.”
  • the nucleotide position of SEQ ED NO:X of the predicted signal sequence is identified as "5' NT of First AA of Signal Pep.”
  • the translated amino acid sequence, beginning with the methionine is identified as "AA SEQ ED NO:Y,” although other reading frames can also be routinely translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.
  • the first and last amino acid position of SEQ ED NO: Y of the predicted signal peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep.”
  • the predicted first amino acid position of SEQ ED NO: Y of the secreted portion is identified as "Predicted First AA of Secreted Portion”.
  • the amino acid position of SEQ ID NO:Y of the last amino acid encoded by the open reading frame is identified in the fifteenth column as "Last AA of ORF'.
  • SEQ ED NO:X (where X may be any of the polynucleotide sequences disclosed in the sequence listing) and the translated SEQ ED NO:Y (where Y may be any of the polypeptide sequences disclosed in the sequence listing) are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below.
  • SEQ ED NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ TD NO:X or the cDNA contained in the deposited clone. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention.
  • polypeptides identified from SEQ ED NO:Y may be used, for example, to generate antibodies which bind specifically to proteins containing the polypeptides and the secreted proteins encoded by the cDNA clones identified in Table 1A and/or elsewhere herein
  • DNA sequences generated by sequencing reactions can contain sequencing errors.
  • the errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence.
  • the erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence.
  • the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).
  • the present invention provides not only the generated nucleotide sequence identified as SEQ ED NO:X, and the predicted translated amino acid sequence identified as SEQ TD NO:Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table 1A.
  • the nucleotide sequence of each deposited plasmid can readily be determined by sequencing the deposited plasmid in accordance with known methods The predicted amino acid sequence can then be verified from such deposits.
  • amino acid sequence of the protein encoded by a particular plasmid can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.
  • Table 1A Also provided in Table 1A is the name of the vector which contains the cDNA plasmid. Each vector is routinely used in the art. The following additional information is provided for convenience.
  • pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene.
  • Phagemid pBS may be excised from the Lambda Zap and Uni-Zap XR vectors, and phagemid pBK may be excised from the Zap Express vector. Both phagemids may be transformed into E. coli strain XL-1 Blue, also available from Stratagene
  • Vectors pSportl, pCMVSport 1.0, pCMVSport 2.0 and pCMVSport 3.0 were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. See, for instance, Gruber, C. E., et al., Focus 75:59 (1993). Vector lafmid BA (Bento Soares, Columbia University, New York, NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue.
  • Vector pCR ® 2.1 which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. See, for instance, Clark, J. M., Nuc. Acids Res. 76:9677-9686 (1988) and Mead, D. et al, Bio/Technology 9: (1991).
  • the present invention also relates to the genes corresponding to SEQ ED NO:X, SEQ ID NO:Y, and/or a deposited cDNA (cDNA Clone ED).
  • the corresponding gene can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include, but are not limited to, preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.
  • allelic variants, orthologs, and/or species homologs are also provided in the present invention. Procedures known in the art can be used to obtain full-length genes, allelic variants, splice variants, full-length coding portions, orthologs, and/or species homologs of genes corresponding to SEQ ED NO:X and SEQ ED NO:Y using information from the sequences disclosed herein or the clones deposited with the ATCC.
  • allelic variants and/or species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for allelic variants and/or the desired homologue.
  • the present invention provides a polynucleotide comprising, or alternatively consisting of, the nucleic acid sequence of SEQ ED NO:X and or a cDNA contained in ATCC Deposit No.Z.
  • the present invention also provides a polypeptide comprising, or alternatively, consisting of, the polypeptide sequence of SEQ TD NO:Y, a polypeptide encoded by SEQ ED NO:X, and/or a polypeptide encoded by a cDNA contained in ATCC deposit No.Z.
  • Polynucleotides encoding a polypeptide comprising, or alternatively consisting of the polypeptide sequence of SEQ ED NO:Y, a polypeptide encoded by SEQ ED NO:X and/or a polypeptide encoded by the cDNA contained in ATCC Deposit No.Z, are also encompassed by the invention.
  • the present invention further encompasses a polynucleotide comprising, or alternatively consisting of the complement of the nucleic acid sequence of SEQ ED NO:X, and/or the complement of the coding strand of the cDNA contained in ATCC Deposit No.Z.
  • the first column in Table IB.l and Table 1B.2 provides the gene number in the application corresponding to the clone identifier.
  • the second column in Table IB.l and Table 1B.2 provides a unique "Clone ID:" for the cDNA clone related to each contig sequence disclosed in Table IB.l and Table IB.2.
  • This clone ID references the cDNA clone which contains at least the 5' most sequence of the assembled contig and at least a portion of SEQ ID NO:X as determined by directly sequencing the referenced clone.
  • the referenced clone may have more sequence than described in the sequence listing or the clone may have less.
  • a full-length cDNA can be obtained by methods described elsewhere herein.
  • the third column in Table IB.l and Table 1B.2 provides a unique "Contig ID” identification for each contig sequence.
  • the fourth column in Table IB.l and Table 1B.2 provides the "SEQ ID NO:" identifier for each of the contig polynucleotide sequences disclosed in Table IB.
  • Table IB.l The fifth column in Table IB.l, "ORF (From-To)", provides the location (i.e., nucleotide position numbers) within the polynucleotide sequence "SEQ ID NO:X” that delineate the preferred open reading frame (ORF) shown in the sequence listing and referenced in Table IB.l, column 6, as SEQ ID NO:Y. Where the nucleotide position number "To" is lower than the nucleotide position number "From", the preferred ORF is the reverse complement of the referenced polynucleotide sequence.
  • the sixth column in Table IB.l provides the corresponding SEQ K) NO:Y for the polypeptide sequence encoded by the preferred ORF delineated in column 5.
  • the invention provides an amino acid sequence comprising, or alternatively consisting of, a polypeptide encoded by the portion of SEQ ID NO:X delineated by "ORF (From- To)". Also provided are polynucleotides encoding such amino acid sequences and the complementary strand thereto.
  • Column 7 in Table IB.l lists residues comprising epitopes contained in the polypeptides encoded by the preferred ORF (SEQ ID NO:Y), as predicted using the algorithm of Jameson and Wolf, (1988) Comp. Appl. Biosci. 4: 181-186.
  • polypeptides of the invention comprise, or alternatively consist of, at least one, two, three, four, five or more of the predicted epitopes as described in Table IB. It will be appreciated that depending on the analytical criteria used to predict antigenic determinants, the exact address of the determinant may vary slightly.
  • Chromosomal location was determined by finding exact matches to EST and cDNA sequences contained in the NCBI (National Center for Biotechnology Information) UniGene database. Each sequence in the UniGene database is assigned to a "cluster"; all of the ESTs, cDNAs, and STSs in a cluster are believed to be derived from a single gene. Chromosomal mapping data is often available for one or more sequence(s) in a UniGene cluster; this data (if consistent) is then applied to the cluster as a whole. Thus, it is possible to infer the chromosomal location of a new polynucleotide sequence by determining its identity with a mapped UniGene cluster.
  • a modified version of the computer program BLASTN (Altshul, et al., J. Mol. Biol. 215:403-410 (1990), and Gish, and States, Nat. Genet. 3:266-272) (1993) was used to search the UniGene database for EST or cDNA sequences that contain exact or near-exact matches to a polynucleotide sequence of the invention (the 'Query').
  • a sequence from the UniGene database (the 'Subject') was said to be an exact match if it contained a segment of 50 nucleotides in length such that 48 of those nucleotides were in the same order as found in the Query sequence.
  • a presumptive chromosomal location was determined for a polynucleotide of the invention, an associated disease locus was identified by comparison with a database of diseases which have been experimentally associated with genetic loci.
  • the database used was the Morbid Map, derived from OMIMTM and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD) 2000;. If the putative chromosomal location of a polynucleotide of the invention (Query sequence) was associated with a disease in the Morbid Map database, an OMIM reference identification number was noted in column 9, Table IB.l, labelled "OMIM Disease Reference(s).
  • Table 5 is a key to the OMIM reference identification numbers (column 1), and provides a description of the associated disease in Column 2.
  • the first number in Table 1B.2, column 5 (preceding the colon), represents the tissue/cell source identifier code corresponding to the code and description provided in Table 4.
  • the second number in column 5 represents the number of times a sequence corresponding to the reference polynucleotide sequence was identified in the corresponding tissue/cell source.
  • tissue/cell source identifier codes in which the first two letters are "AR" designate information generated using DNA array technology.
  • cDNAs were amplified by PCR and then transferred, in duplicate, onto the array. Gene expression was assayed through hybridization of first strand cDNA probes to the DNA array.
  • cDNA probes were generated from total RNA extracted from a variety of different tissues and cell lines. Probe synthesis was performed in the presence of 33 P dCTP, using oligo (dT) to prime reverse transcription.
  • H058L1 H0327:l, H0545:l, H0373:l, H0622:l, L0770:l, L076 1, L0644:l, L0803:l, L0774:l, L0805:l, L0655:l, H0539:l, H052 1, H0555:l, L0779:l and S0031:l.
  • AR269 5 AR060:5 AR16 5, AR162:5 AR055:5 AR163 5, AR176 5, AR225 5, AR267:4 AR266:4, AR263:4 AR228:4 AR233:4, AR178:4 AR214:4 AR3094, AR2214,AR1824,AR181:4 AR257:4, AR179:4 AR264:4 AR165:4, AR183:4 AR231.4 AR2394, AR2374, AR2363,AR164:3 AR262:3, AR300:3 AR177:3 AR27L3, AR294:3 AR229:3 AR1663, AR2723, AR2553, AR299:3 AR275:3, AR172:3 AR234:3 AR195:3, AR215:3 AR173:3 AR2403, AR1963, AR1693,AR168:3 AR213:3, AR185:3 AR268:3 AR29L3, AR31L3 AR270:3 AR2013, AR1753, AR2883,AR261
  • AR308 42 .,, AR192:7, AR205:. ,AR161:: i, AR198:3, AR178:3, AR162:3, AR163:3, AR193:3, AR216:3,
  • AR254 2 AR215:2, AR053:2 AR257:2 AR17 2, AR195:2, AR27 2, AR20L2, AR277:2, AR266:2,
  • Table 1C summarizes additional polynucleotides encompassed by the invention (including cDNA clones related to the sequences (Clone ID:), contig sequences (contig identifier (Contig ID:) contig nucleotide sequence identifiers (SEQ ID NO:X)), and genomic sequences (SEQ TD NO:B).
  • the first column provides a unique clone identifier, "Clone ED:”, for a cDNA clone related to each contig sequence.
  • the second column provides the sequence identifier, "SEQ ID NO:X”, for each contig sequence.
  • the third column provides a unique contig identifier, "Contig ID:” for each contig sequence.
  • the fourth column provides a BAC identifier "BAC ID NO:A” for the BAC clone referenced in the corresponding row of the table.
  • the fifth column provides the nucleotide sequence identifier, "SEQ TD NO:B" for a fragment of the BAC clone identified in column four of the corresponding row of the table.
  • the sixth column "Exon From- To" provides the location (i.e., nucleotide position numbers) within the polynucleotide sequence of SEQ ID NO:B which delineate certain polynucleotides of the invention that are also exemplary members of polynucleotide sequences that encode polypeptides of the invention (e.g., polypeptides containing amino acid sequences encoded by the polynucleotide sequences delineated in column six, and fragments and variants thereof).
  • the polynucleotides or polypeptides, or agonists or antagonists of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these * molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides or polypeptides, or agonists or antagonists could be used to treat the associated disease.
  • the present invention encompasses methods of detecting, preventing, diagnosing, prognosticating, treating, and/or ameliorating a disease or disorder.
  • the present invention encompasses a method of treating an immune disease or disorder comprising administering to a patient in which such detection, treatment, prevention, and/or amelioration is desired a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) in an amount effective to detect, prevent, diagnose, prognosticate, treat, and/or ameliorate the immune disease or disorder.
  • the present invention also encompasses methods of detecting, preventing, diagnosing, prognosticating, treating, and/or ameliorating an immune disease or disorder; comprising administering to a patient combinations of the proteins, nucleic acids, or antibodies of the invention (or fragments or variants thereof), sharing similar indications as shown in the corresponding rows in Column 3 of Table ID.
  • Table ID provides information related to biological activities for polynucleotides and polypeptides of the invention (including antibodies, agonists, and/or antagonists thereof). Table ID also provides information related to assays which may be used to test polynucleotides and polypeptides of the invention (including antibodies, agonists, and/or antagonists thereof) for the corresponding biological activities.
  • the first column (“Gene No.") provides the gene number in the application for each clone identifier.
  • the second column (“cDNA Clone ID:”) provides the unique clone identifier for each clone as previously described and indicated in Table 1A through Table ID.
  • the third column (“AA SEQ ID NO:Y”) indicates the Sequence Listing SEQ ID Number for polypeptide sequences encoded by the corresponding cDNA clones (also as indicated in Tables 1A, Table IB, and Table 2).
  • the fourth column (“Biological Activity”) indicates a biological activity corresponding to the indicated polypeptides (or polynucleotides encoding said polypeptides).
  • the fifth column (“Exemplary Activity Assay”) further describes the corresponding biological activity and also provides information pertaining to the various types of assays which may be performed to test, demonstrate, or quantify the corresponding biological activity.
  • Fluorometric microvolume assay technology is a fluorescence-based system which provides a means to perform nonradioactive cell- and bead- based assays to detect activation of cell signal transduction pathways. This technology was designed specifically for ligand binding and immunological assays. Using this technology, fluorescent cells or beads at the bottom of the well are detected as localized areas of concentrated fluorescence using a data processing system. Unbound flurophore comprising the background signal is ignored, allowing for a wide variety of homogeneous assays.
  • FMAT technology may be used for peptide ligand binding assays, immunofluorescence, apoptosis, cytotoxicity, and bead- based immunocapture assays. See, Miraglia S et. al., "Homogeneous cell and bead based assays for highthroughput screening using flourometric microvolume assay technology," Journal of Biomolecular Screening; 4:193-204 (1999).
  • FMAT technology may be used to test, confirm, and/or identify the ability of polypeptides (including polypeptide fragments and variants) to activate signal transduction pathways.
  • FMAT technology may be used to test, confirm, and/or identify the ability of polypeptides to upregulate production of immunomodulatory proteins (such as, for example, interleukins, GM-CSF, Rantes, and Tumor Necrosis factors, as well as other cellular regulators (e.g. insulin)).
  • immunomodulatory proteins such as, for example, interleukins, GM-CSF, Rantes, and Tumor Necrosis factors, as well as other cellular regulators (e.g. insulin)).
  • Table ID also describes the use of kinase assays for testing, demonstrating, or quantifying biological activity.
  • the phosphorylation and de-phosphorylation of specific amino acid residues e.g. Tyrosine, Serine, Threonine
  • cell-signal transduction proteins provides a fast, reversible means for activation and de-activation of cellular signal transduction pathways.
  • cell signal transduction via phosphorylation/de-phosphorylation is crucial to the regulation of a wide variety of cellular processes (e.g. proliferation, differentiation, migration, apoptosis, etc.).
  • kinase assays provide a powerful tool useful for testing, confirming, and/or identifying polypeptides (including polypeptide fragments and variants) that mediate cell signal transduction events via protein phosphorylation. See e.g., Forrer, P., Tamaskovic R., and Jaussi, R. "Enzyme-Linked Immunosorbent Assay for Measurement of JNK, ERK, and p38 Kinase Activities" Biol. Chem. 379(8-9): 1101-1110 (1998). Table ID

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des polypeptides sécrétés humains, ainsi que des molécules d'acides nucléiques isolés codant lesdits polypeptides, servant à diagnostiquer et à traiter des maladies et des affections auto-immunes. L'invention concerne également des anticorps qui fixent ces polypeptides, ainsi que des vecteurs, des cellules hôtes, des méthodes de recombinaison et de synthèse pour produire lesdits polynucléotides, polypeptides et/ou anticorps. L'invention concerne en outre des méthodes de criblage servant à identifier des agonistes et des antagonistes des polynucléotides et polypeptides de l'invention. Elle concerne enfin des méthodes et des compositions servant à inhiber ou stimuler la production et la fonction des polypeptides de l'invention.
PCT/US2002/008278 1997-03-07 2002-03-19 Proteines secretees humaines WO2002102994A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002441832A CA2441832A1 (fr) 2001-03-21 2002-03-19 Proteines secretees humaines
EP02760994A EP1379132A4 (fr) 2001-03-21 2002-03-19 Proteines secretees humaines
AU2002326293A AU2002326293A1 (en) 2001-03-21 2002-03-19 Human secreted proteins
US11/346,470 US20060223088A1 (en) 1997-03-07 2006-02-03 Human secreted proteins
US12/198,817 US7968689B2 (en) 1997-03-07 2008-08-26 Antibodies to HSDEK49 polypeptides

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US27734001P 2001-03-21 2001-03-21
US60/277,340 2001-03-21
US30617101P 2001-07-19 2001-07-19
US60/306,171 2001-07-19
US33128701P 2001-11-13 2001-11-13
US60/331,287 2001-11-13

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US09/981,876 Continuation-In-Part US7053190B2 (en) 1997-03-07 2001-10-19 Secreted protein HRGDF73
US10/100,683 Continuation-In-Part US7368531B2 (en) 1997-03-07 2002-03-19 Human secreted proteins

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10472532 A-371-Of-International 2002-03-19
US11/346,470 Continuation-In-Part US20060223088A1 (en) 1997-03-07 2006-02-03 Human secreted proteins

Publications (2)

Publication Number Publication Date
WO2002102994A2 true WO2002102994A2 (fr) 2002-12-27
WO2002102994A3 WO2002102994A3 (fr) 2003-07-24

Family

ID=27402891

Family Applications (7)

Application Number Title Priority Date Filing Date
PCT/US2002/008123 WO2002102993A2 (fr) 1997-03-07 2002-03-19 Proteines secretees par l'homme
PCT/US2002/008124 WO2003004622A2 (fr) 1997-03-07 2002-03-19 Proteines humaines secretees
PCT/US2002/008278 WO2002102994A2 (fr) 1997-03-07 2002-03-19 Proteines secretees humaines
PCT/US2002/008277 WO2003038063A2 (fr) 2001-03-21 2002-03-19 Proteines secretees humaines
PCT/US2002/009785 WO2002095010A2 (fr) 1997-03-07 2002-03-19 Proteines secretees humaines
PCT/US2002/008276 WO2002076488A1 (fr) 1997-03-07 2002-03-19 Proteines humaines secretees
PCT/US2002/008279 WO2002090526A2 (fr) 1997-03-07 2002-03-19 Proteines secretees par les humains

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PCT/US2002/008123 WO2002102993A2 (fr) 1997-03-07 2002-03-19 Proteines secretees par l'homme
PCT/US2002/008124 WO2003004622A2 (fr) 1997-03-07 2002-03-19 Proteines humaines secretees

Family Applications After (4)

Application Number Title Priority Date Filing Date
PCT/US2002/008277 WO2003038063A2 (fr) 2001-03-21 2002-03-19 Proteines secretees humaines
PCT/US2002/009785 WO2002095010A2 (fr) 1997-03-07 2002-03-19 Proteines secretees humaines
PCT/US2002/008276 WO2002076488A1 (fr) 1997-03-07 2002-03-19 Proteines humaines secretees
PCT/US2002/008279 WO2002090526A2 (fr) 1997-03-07 2002-03-19 Proteines secretees par les humains

Country Status (4)

Country Link
EP (7) EP1404702A4 (fr)
AU (6) AU2002363296A1 (fr)
CA (7) CA2441416A1 (fr)
WO (7) WO2002102993A2 (fr)

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1341803A4 (fr) * 2000-11-30 2005-01-05 Nuvelo Inc Nouveaux acides nucleiques et polypeptides
US6887975B2 (en) 1998-06-01 2005-05-03 Agensys, Inc. Peptides derived from STEAP1
US7097990B2 (en) 2001-10-12 2006-08-29 Astellas Pharma Inc. Method of screening cell death inhibitor
US7105644B2 (en) 1997-07-08 2006-09-12 Human Genome Sciences, Inc. Secreted protein HHTLF25 antibodies
WO2006138219A2 (fr) * 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Procedes d'evaluation de patients
US7196164B2 (en) 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
US7361475B2 (en) 2000-10-31 2008-04-22 Diadexus, Inc. Compositions and methods relating to colon specific genes and proteins
EP1670947A4 (fr) * 2003-09-23 2008-11-05 Univ North Carolina Technique et composition de correlation de polymorphisme nucleotidique simple dans le gene vitamine k epoxyde reductase et le dosage de warfarine
US7455991B2 (en) 1999-06-01 2008-11-25 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US20090054307A1 (en) * 2005-09-01 2009-02-26 Howard Florey Institute Of Experimental Physiology And Medicine Prophylactic and therapeutic agents and uses therefor
US7622569B2 (en) 1998-06-01 2009-11-24 Agensys, Inc. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US7645602B2 (en) 2003-09-23 2010-01-12 The University Of North Carolina At Chapel Hill Methods and compositions for producing vitamin K dependent proteins
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US7884179B2 (en) 2001-09-06 2011-02-08 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
US7947459B2 (en) 1998-06-01 2011-05-24 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
EP2333112A2 (fr) 2004-02-20 2011-06-15 Veridex, LLC Pronostics de cancer du sein
US8008450B2 (en) 2003-05-08 2011-08-30 Abbott Biotherapeutics Corp. Therapeutic use of anti-CS1 antibodies
US8008442B2 (en) 2004-04-22 2011-08-30 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US8012937B2 (en) 1998-06-01 2011-09-06 Agensys, Inc. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US8030457B2 (en) 2007-08-23 2011-10-04 Amgen, Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8093222B2 (en) * 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US8188233B2 (en) 2008-02-07 2012-05-29 Merck Sharp & Dohme Corp. 1B20 PCSK9 antagonists
US8188234B2 (en) 2008-02-07 2012-05-29 Merck Sharp & Dohme Corp. 1D05 PCSK9 antagonists
US8263353B2 (en) 2007-03-27 2012-09-11 Merck Sharp & Dohme Corp. Method for detecting autoprocessed, secreted PCSK9
US8344114B2 (en) 2006-11-07 2013-01-01 Merck Sharp & Dohme Corp. Antagonists of PCSK9
US8436147B2 (en) 2006-10-27 2013-05-07 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US8440189B2 (en) 1999-01-15 2013-05-14 Biogen Idec Ma Inc. Antagonists of TWEAK and of TWEAK receptor and their use to treat immunological disorders
US20130318640A1 (en) * 2003-10-14 2013-11-28 Baxter International Inc. Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives
US8728475B2 (en) 2005-05-10 2014-05-20 Biogen Idec Ma Inc. Methods for treating inflammatory bowel disease
US8748115B2 (en) 2008-12-12 2014-06-10 Merck Sharp & Dohme Corp. PCSK9 immunoassay
US8802827B2 (en) 2009-10-30 2014-08-12 Merck Sharp & Dohme Corp. AX1 PCSK9 antagonists
US8877900B2 (en) 2009-10-30 2014-11-04 Merck Sharp & Dohme Corp. AX132 PCSK9 antagonists
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9011859B2 (en) 2002-04-09 2015-04-21 Biogen Idec Ma Inc. Methods for treating TWEAK-related conditions
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9068012B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9617523B2 (en) 2005-02-28 2017-04-11 Baxalta GmbH Nucleic acids encoding vitamin K expoxide reductase subunit 1 and vitamin K dependent protein expression and methods of using same
US9631002B2 (en) 2010-12-21 2017-04-25 The University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin K-dependent proteins
US9682218B2 (en) 2013-12-23 2017-06-20 Carefusion 2200, Inc. Pleurodesis device and method
US9775899B2 (en) 2005-02-17 2017-10-03 Biogen Ma Inc. Treating neurological disorders
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
WO2018119354A1 (fr) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Édition génique de pcsk9
US10618955B2 (en) 2014-07-15 2020-04-14 Kymab Limited Methods for treating neurodegenerative disease using anti-PD-1 antibodies
US11180571B2 (en) 2017-04-03 2021-11-23 Hoffmann-La Roche Inc. Antibodies binding to STEAP-1
US11753479B2 (en) 2014-03-04 2023-09-12 Kymab Limited Nucleic acids encoding anti-OX40L antibodies
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
US12029795B2 (en) 2020-04-09 2024-07-09 Verve Therapeutics, Inc. Base editing of PCSK9 and methods of using same for treatment of disease
US12209128B2 (en) 2016-06-20 2025-01-28 Kymab Limited Anti-PD-L1 antibodies

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7335731B2 (en) 2000-07-25 2008-02-26 Genentech, Inc. PRO4332 polypeptides
EP1666490A3 (fr) * 2000-07-25 2006-11-02 Genentech, Inc. Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci
AU2002318112B2 (en) 2001-04-10 2007-12-06 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20030119112A1 (en) 2001-06-20 2003-06-26 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2003900747A0 (en) * 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
WO2005019258A2 (fr) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions et methodes de traitement de maladies relatives au systeme immunitaire
EP1714154A2 (fr) * 2004-02-03 2006-10-25 Bayer HealthCare AG Agents diagnostiques et therapeutiques pour des maladies associes a la glutamate carboxypeptidase (pgcp) plasmatique
AU2005282889B2 (en) 2004-09-01 2012-03-15 Dynavax Technologies Corporation Methods and conpositions for inhibition of innate immune responses and autoimmunity
CA2579705A1 (fr) * 2004-09-07 2006-03-16 Telethon Institute For Child Health Research Methode de diagnostic et/ou de prediction du developpement d'une affection allergique
EP2093297A3 (fr) * 2004-09-07 2009-11-18 Telethon Institute for Child Health Research Agents de traitement ou de prévention d'un trouble allergique
GB0521488D0 (en) * 2005-10-21 2005-11-30 Ares Trading Sa Integral membrane protein
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
AU2008317261B2 (en) 2007-10-26 2015-04-09 Dynavax Technologies Corporation Methods and compositions for inhibition of immune responses and autoimmunity
EP3536336A1 (fr) * 2007-11-30 2019-09-11 Siemens Healthcare Diagnostics Inc. Fragments de récepteur de l'adiponectine et procédés d'utilisation
EA201291357A1 (ru) 2010-06-16 2013-11-29 Дайнэвокс Текнолоджиз Корпорейшн Способы лечения с применением ингибиторов tlr7 и/или tlr9
PE20171640A1 (es) 2010-09-22 2017-11-09 Alios Biopharma Inc Analogos de nucleotidos sustituidos
EP2794630A4 (fr) 2011-12-22 2015-04-01 Alios Biopharma Inc Analogues de nucléotide phosphorothioate substitués
CN104321333A (zh) 2012-03-21 2015-01-28 沃泰克斯药物股份有限公司 硫代氨基磷酸酯核苷酸前药的固体形式
WO2013142157A1 (fr) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Combinaisons pharmaceutiques comprenant un analogue thionucléotidique
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
ES2963042T3 (es) 2017-06-22 2024-03-25 Procter & Gamble Películas que incluyen una capa soluble en agua y un recubrimiento orgánico depositado por vapor
CN110719968A (zh) 2017-06-22 2020-01-21 宝洁公司 包括水溶性层和气相沉积无机涂层的膜

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100236393B1 (ko) * 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
WO2000004140A1 (fr) * 1998-07-15 2000-01-27 Human Genome Sciences, Inc. 71 proteines humaines secretees
WO2002026931A2 (fr) * 2000-09-25 2002-04-04 Human Genome Sciences, Inc. 71 proteines humaines secretees
US5858716A (en) * 1997-05-30 1999-01-12 Smithkline Beecham Corporation H2CAA71 polynucleotides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [Online] SANGER CENTRE, HINXTON, UK 27 November 2000 PEARCE A.: 'Human DNA sequence from clone RP11-50D16 on chromosome 13, complete sequence', XP002963946 Retrieved from EMBL Database accession no. (AL445590) *
See also references of EP1379132A2 *

Cited By (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105644B2 (en) 1997-07-08 2006-09-12 Human Genome Sciences, Inc. Secreted protein HHTLF25 antibodies
US7196164B2 (en) 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
US7575749B2 (en) 1998-06-01 2009-08-18 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US6887975B2 (en) 1998-06-01 2005-05-03 Agensys, Inc. Peptides derived from STEAP1
US8012937B2 (en) 1998-06-01 2011-09-06 Agensys, Inc. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US7947459B2 (en) 1998-06-01 2011-05-24 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US7622569B2 (en) 1998-06-01 2009-11-24 Agensys, Inc. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US8440189B2 (en) 1999-01-15 2013-05-14 Biogen Idec Ma Inc. Antagonists of TWEAK and of TWEAK receptor and their use to treat immunological disorders
US8241626B2 (en) 1999-06-01 2012-08-14 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US7455991B2 (en) 1999-06-01 2008-11-25 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US7361475B2 (en) 2000-10-31 2008-04-22 Diadexus, Inc. Compositions and methods relating to colon specific genes and proteins
EP1341803A4 (fr) * 2000-11-30 2005-01-05 Nuvelo Inc Nouveaux acides nucleiques et polypeptides
US8013135B2 (en) 2001-09-06 2011-09-06 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US7947276B2 (en) 2001-09-06 2011-05-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US9029516B2 (en) 2001-09-06 2015-05-12 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US7939503B2 (en) 2001-09-06 2011-05-10 Agensys, Inc. Reduction of cell-cell communication in prostate cancer using STEAP-1 siRNA
US7884179B2 (en) 2001-09-06 2011-02-08 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
US7097990B2 (en) 2001-10-12 2006-08-29 Astellas Pharma Inc. Method of screening cell death inhibitor
US9011859B2 (en) 2002-04-09 2015-04-21 Biogen Idec Ma Inc. Methods for treating TWEAK-related conditions
US9175081B2 (en) 2003-05-08 2015-11-03 Abbvie Biotherapeutics Inc. Therapeutic use of anti-CS1 antibodies
US8088898B2 (en) 2003-05-08 2012-01-03 Abbott Biotherapeutics Corp. Therapeutic use of anti-CS1 antibodies
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US8436146B2 (en) 2003-05-08 2013-05-07 Abbvie Biotherapeutics Inc. Therapeutic use of anti-CS1 antibodies
US8008450B2 (en) 2003-05-08 2011-08-30 Abbott Biotherapeutics Corp. Therapeutic use of anti-CS1 antibodies
US8349330B2 (en) 2003-05-08 2013-01-08 Abbott Biotherapeutics Corp. Therapeutic use of anti-CS1 antibodies
US8461306B2 (en) 2003-05-08 2013-06-11 Abbvie Biotherapeutics Inc. Therapeutic use of anti-CS1 antibodies
US8445646B2 (en) 2003-05-08 2013-05-21 Abbvie Biotherapeutics Inc. Therapeutic use of anti-CS1 antibodies
US8444980B2 (en) 2003-05-08 2013-05-21 Abbvie Biotherapeutics Inc. Therapeutic use of anti-CS1 antibodies
US10442859B2 (en) 2003-05-08 2019-10-15 Abbvie Biotherapeutics Inc. Therapeutic use of anti-CS1 antibodies
US8133981B2 (en) 2003-05-08 2012-03-13 Abbott Biotherapeutics Corp. Therapeutic use of anti-CS1 antibodies
US7645602B2 (en) 2003-09-23 2010-01-12 The University Of North Carolina At Chapel Hill Methods and compositions for producing vitamin K dependent proteins
EP1670947A4 (fr) * 2003-09-23 2008-11-05 Univ North Carolina Technique et composition de correlation de polymorphisme nucleotidique simple dans le gene vitamine k epoxyde reductase et le dosage de warfarine
US8097410B2 (en) 2003-09-23 2012-01-17 University Of North Carolina At Chapel Hill Methods and compositions for vitamin K epoxide reductase
US7524665B2 (en) 2003-09-23 2009-04-28 University Of North Carolina At Chapel Hill Methods and compositions for vitamin K epoxide reductase
EP2380985A1 (fr) * 2003-09-23 2011-10-26 University of North Carolina at Chapel Hill Cellules exprimantes la vitamine K epoxyde réductase et utilisation des-dites.
US7687233B2 (en) 2003-09-23 2010-03-30 The University Of North Carolina At Chapel Hill Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin K epoxide reductase gene and warfarin dosage
US7858318B2 (en) 2003-09-23 2010-12-28 The University Of North Carolina At Chapel Hill Methods and compositions for vitamin K epoxide reductase
US8426128B2 (en) 2003-09-23 2013-04-23 The University Of North Carolina At Chapel Hill Methods and compositions for vitamin K epoxide reductase
US9441208B2 (en) 2003-09-23 2016-09-13 The University Of North Carolina At Chapel Hill Methods and compositions for producing vitamin K dependent proteins
US20130318640A1 (en) * 2003-10-14 2013-11-28 Baxter International Inc. Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives
EP2333112A2 (fr) 2004-02-20 2011-06-15 Veridex, LLC Pronostics de cancer du sein
US8008442B2 (en) 2004-04-22 2011-08-30 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US11401347B2 (en) 2004-04-22 2022-08-02 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US10597463B2 (en) 2004-04-22 2020-03-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US9617346B2 (en) 2004-04-22 2017-04-11 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US9023605B2 (en) 2004-04-22 2015-05-05 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US9775899B2 (en) 2005-02-17 2017-10-03 Biogen Ma Inc. Treating neurological disorders
US9617523B2 (en) 2005-02-28 2017-04-11 Baxalta GmbH Nucleic acids encoding vitamin K expoxide reductase subunit 1 and vitamin K dependent protein expression and methods of using same
US9828588B2 (en) 2005-03-15 2017-11-28 The University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin K-dependent proteins
US8603823B2 (en) 2005-03-15 2013-12-10 The University Of North Carolina At Chapel Hill Methods and compositions for producing vitamin K dependent proteins
US8728475B2 (en) 2005-05-10 2014-05-20 Biogen Idec Ma Inc. Methods for treating inflammatory bowel disease
US9730947B2 (en) 2005-06-13 2017-08-15 Biogen Ma Inc. Method of treating lupus nephritis
WO2006138219A3 (fr) * 2005-06-13 2007-04-12 Biogen Idec Inc Procedes d'evaluation de patients
WO2006138219A2 (fr) * 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Procedes d'evaluation de patients
US8048635B2 (en) 2005-06-13 2011-11-01 Biogen Idec Ma Inc. Measurement of soluble Tweak levels for evaluation of lupus patients
US20090054307A1 (en) * 2005-09-01 2009-02-26 Howard Florey Institute Of Experimental Physiology And Medicine Prophylactic and therapeutic agents and uses therefor
US8436147B2 (en) 2006-10-27 2013-05-07 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US9593167B2 (en) 2006-10-27 2017-03-14 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US8889847B2 (en) 2006-10-27 2014-11-18 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US8344114B2 (en) 2006-11-07 2013-01-01 Merck Sharp & Dohme Corp. Antagonists of PCSK9
US8664190B2 (en) 2006-11-27 2014-03-04 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US8912160B2 (en) 2006-11-27 2014-12-16 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US11530410B2 (en) 2006-11-27 2022-12-20 Ionis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US9650636B2 (en) 2006-11-27 2017-05-16 Ionis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US8093222B2 (en) * 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US8263353B2 (en) 2007-03-27 2012-09-11 Merck Sharp & Dohme Corp. Method for detecting autoprocessed, secreted PCSK9
US9920134B2 (en) 2007-08-23 2018-03-20 Amgen Inc. Monoclonal antibodies to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8168762B2 (en) 2007-08-23 2012-05-01 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US9056915B2 (en) 2007-08-23 2015-06-16 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US9045547B2 (en) 2007-08-23 2015-06-02 Amgen Inc. Methods of using antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8030457B2 (en) 2007-08-23 2011-10-04 Amgen, Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8188233B2 (en) 2008-02-07 2012-05-29 Merck Sharp & Dohme Corp. 1B20 PCSK9 antagonists
US8957194B2 (en) 2008-02-07 2015-02-17 Merck Sharpe & Dohme Corp. 1B20 PCSK9 antagonists
US8697070B2 (en) 2008-02-07 2014-04-15 Merck Sharp & Dohme Corp. 1D05 PCSK9 antagonists
US8188234B2 (en) 2008-02-07 2012-05-29 Merck Sharp & Dohme Corp. 1D05 PCSK9 antagonists
US8748115B2 (en) 2008-12-12 2014-06-10 Merck Sharp & Dohme Corp. PCSK9 immunoassay
US8877900B2 (en) 2009-10-30 2014-11-04 Merck Sharp & Dohme Corp. AX132 PCSK9 antagonists
US8802827B2 (en) 2009-10-30 2014-08-12 Merck Sharp & Dohme Corp. AX1 PCSK9 antagonists
US9631002B2 (en) 2010-12-21 2017-04-25 The University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin K-dependent proteins
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US10611849B2 (en) 2013-12-17 2020-04-07 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9040052B1 (en) 2013-12-17 2015-05-26 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US11434305B2 (en) 2013-12-17 2022-09-06 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US10618971B2 (en) 2013-12-17 2020-04-14 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9682218B2 (en) 2013-12-23 2017-06-20 Carefusion 2200, Inc. Pleurodesis device and method
US11273292B2 (en) 2013-12-23 2022-03-15 Carefusion 2200, Inc. Autologous pleurodesis methods and devices
US11753479B2 (en) 2014-03-04 2023-09-12 Kymab Limited Nucleic acids encoding anti-OX40L antibodies
US11773175B2 (en) 2014-03-04 2023-10-03 Kymab Limited Antibodies, uses and methods
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US10711059B2 (en) 2014-07-15 2020-07-14 Kymab Limited Methods for treating neurodegenerative diseases using anti-PD-L1 antibodies
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US10618955B2 (en) 2014-07-15 2020-04-14 Kymab Limited Methods for treating neurodegenerative disease using anti-PD-1 antibodies
US11555066B2 (en) 2014-07-15 2023-01-17 Kymab Limited Precision medicine for cholesterol treatment
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9068012B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US12209128B2 (en) 2016-06-20 2025-01-28 Kymab Limited Anti-PD-L1 antibodies
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
WO2018119354A1 (fr) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Édition génique de pcsk9
US11685790B2 (en) 2017-04-03 2023-06-27 Hoffmann-La Roche Inc. Antibodies binding to STEAP-1
US12129306B2 (en) 2017-04-03 2024-10-29 Hoffman-La Roche Inc. Antibodies binding to STEAP-1
US11180571B2 (en) 2017-04-03 2021-11-23 Hoffmann-La Roche Inc. Antibodies binding to STEAP-1
US12029795B2 (en) 2020-04-09 2024-07-09 Verve Therapeutics, Inc. Base editing of PCSK9 and methods of using same for treatment of disease

Also Published As

Publication number Publication date
AU2002326293A1 (en) 2003-01-02
EP1379264A4 (fr) 2009-07-08
EP1414845A2 (fr) 2004-05-06
WO2002090526A2 (fr) 2002-11-14
EP1379132A2 (fr) 2004-01-14
EP1379264A1 (fr) 2004-01-14
CA2441397A1 (fr) 2002-10-03
WO2003004622A3 (fr) 2004-02-19
EP1390390A2 (fr) 2004-02-25
EP1404702A4 (fr) 2009-07-08
EP1390390A4 (fr) 2009-07-08
WO2002076488A1 (fr) 2002-10-03
CA2441702A1 (fr) 2002-12-27
AU2002332391A1 (en) 2003-01-02
EP1381622A2 (fr) 2004-01-21
AU2002354719A1 (en) 2003-01-21
WO2002102994A3 (fr) 2003-07-24
EP1414845A4 (fr) 2009-07-08
WO2003038063A2 (fr) 2003-05-08
CA2441417A1 (fr) 2002-11-14
CA2441832A1 (fr) 2002-12-27
CA2441755A1 (fr) 2003-05-08
AU2002363296A1 (en) 2003-05-12
AU2002320013A1 (en) 2002-11-18
WO2003038063A3 (fr) 2003-12-11
WO2002095010A3 (fr) 2004-02-12
WO2002095010A2 (fr) 2002-11-28
WO2002102993A3 (fr) 2004-03-25
WO2003004622A2 (fr) 2003-01-16
EP1379132A4 (fr) 2009-07-01
EP1404702A2 (fr) 2004-04-07
WO2002102993A2 (fr) 2002-12-27
EP1423134A2 (fr) 2004-06-02
CA2441840A1 (fr) 2002-11-28
CA2441416A1 (fr) 2003-01-16
AU2002324424A1 (en) 2002-12-03
WO2002090526A3 (fr) 2003-10-30

Similar Documents

Publication Publication Date Title
US20030224461A1 (en) Nucleic acids, proteins, and antibodies
WO2002102994A2 (fr) Proteines secretees humaines
WO2001055318A2 (fr) Acides nucleiques, proteines et anticorps
WO2002000677A1 (fr) Acides nucleiques, proteines et anticorps
WO2001090304A2 (fr) Acides nucleiques, proteines et anticorps
WO2001059063A2 (fr) Acides nucleiques, proteines et anticorps
WO2001055317A2 (fr) Acides nucleiques, proteines et anticorps
WO2002077186A2 (fr) Proteines secretees par l'etre humain
WO2001055441A2 (fr) Acides nucléiques, protéines et anticorps
US20050208602A1 (en) 89 human secreted proteins
WO2002068628A1 (fr) 70 proteines humaines secretees
EP1259526A2 (fr) Acides nucleiques, proteines et anticorps
WO2002057420A2 (fr) 50 proteines secretees humaines
EP1252337A2 (fr) Acides nucleiques, proteines et anticorps
WO2001055329A2 (fr) Acides nucleiques, proteines et anticorps

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2441832

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002760994

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2002760994

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载